글로벌 간세포암 약물 시장 – 2030년까지의 산업 동향 및 예측

간세포암 치료제 시장 분석 및 규모

HCC의 발병률은 지난 수십 년 동안 상당히 증가했으며 전 세계적으로 암으로 인한 사망의 세 번째 주요 원인이 되었습니다. B형 간염과 C형 간염 만성 간 질환의 발병률이 증가하고 있으며, HCC의 발병률은 아시아와 아프리카에서 만연하며 남성의 유병률은 10만 명당 35명입니다.

Data Bridge Market Research는 2023-2030년 예측 기간 동안 간세포암 약물 시장의 성장률을 분석합니다. 간세포암 약물 시장의 예상 CAGR은 언급된 예측 기간 동안 약 8.2%인 경향이 있습니다. 시장은 2022년에 10억 4천만 달러로 평가되었으며 2030년까지 19억 5천만 달러로 성장할 것입니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

간세포암 치료제 시장 범위 및 세분화

Market Definition

Hepatocellular carcinoma (HCC) is a major kind of primary liver cancer which arises from the liver cells or hepatocytes. The disease is more prevalent in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of this condition is largely done by several imaging tests such as ultrasound, CT scan, MRI, and liver biopsy. Treatment includes ablation therapy in addition to chemotherapy, radiation therapy, and targeted drug therapy. Mjority of HCC is witnessed in patients with end-stage liver dysfunction.  

Hepatocellular Carcinoma Drugs Market Dynamics

Drivers

• Increased Prevalence of Liver Cancer

According to the survey by the Health Science Department, University of California, Los Angeles, (UCLA), 2017, hepatocellular carcinoma (HCC) accounts for three quarters of liver cancers in the U.S. with almost 40,000 Americans diagnosed with liver cancer in 2017 and above 28,000 deaths are reported from the disease. Furthermore, in April 2018, Eli Lilly and Company completed Phase 3 research study of Cyramza as a single agent in the second-line treatment of people suffering from hepatocellular carcinoma.

• Rising Approval of Novel Drugs

There are several clinical advancements combined with the approval of novel drugs by the regulatory agencies for the treatment of hepatocellular carcinoma is enhancing growth of the market. For instance, in April 2017, the U.S. FDA expanded the indications of regorafenib manufactured by Bayer HealthCare Pharmaceuticals Inc., for treatment of patients suffering from hepatocellular carcinoma. The therapy showed major improvement in survival for patients after the failure of standard treatments. Furthermore, in 2017, the U.S. FDA granted accelerated approval for nivolumab (Opdivo) drug developed by Bristol-Myers Squibb for treating hepatocellular carcinoma.

Opportunities

• Increasing Strategic Collaborations Between Organizations

The manufactures are focused on several strategic collaborations to jointly develop and commercialize immunotherapies that are indicated to treat wide range of tumors. For instance, in 2014, Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. made a strategic collaboration agreement to jointly develop and commercialize several immunotherapies as single and combination therapies with Opdivo, to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan. Additionally, in 2015, Novartis Pharmaceuticals initiated the Phase 2 trials to compare the safety and efficacy for dovitinib and sorafenib in adult patients for treating advanced hepatocellular carcinoma.

• Increasing Prevalence of Hepatocellular Carcinoma

According to the latest research by International Journal of Cancer Research and Treatment, 2014, HCC is the sixth most common type of cancer worldwide and third most common cause of death worldwide, fifth for men and eighth for women. The disease accounts for more than 5% of all cancers and for 80-90% of primary liver cancers. Furthermore, as per the Addis Ababa University, 2017, hepatocellular carcinoma (HCC) resulted in around 854,000 new cases of liver cancer and 810,000 related deaths in 2015

 Restraints/Challenges

• Lack of Drug Approvals

The extreme lack of drug approvals by authorized organizations is hampering the market growth. There are no FDA-approved drugs to treat HCC. Additionally, the limited availability of treatment processes can limit market growth.

• High Cost of Treatment

The rising expenditure associated with the various medications impede the market growth. Additionally, several diagnostic procedures including imaging procedures and liver tissue examination hamper the market's growth.

This hepatocellular carcinoma drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hepatocellular carcinoma drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hepatocellular Carcinoma Drugs Market Scope

The hepatocellular carcinoma drugs market is segmented on the basis of drug class, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• PD-1/PD-L1 Inhibitors
• Atezolizumab (Tecentriq)
• Avelumab (Bavencio)
• Durvalumab (Imfinzi)
• Tyrosine Kinase Inhibitors
• Gefitinib
• Erlotinib
• Sorafenib
• Treatment

Treatment Type

• Medication
• Surgery
• Radiotherapy
• Chemotherapy
• Others

Route of Administration

• Oral
• Injectable
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Hepatocellular Carcinoma Drugs Market Regional Analysis/Insights

The hepatocellular carcinoma drugs market is analyzed and market size insights and trends are provided by drug class, treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the hepatocellular carcinoma drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has witnessed the highest growth for hepatocellular carcinoma drugs market throughout the forecasted period due to the developing number of R&D activities attempted by the companies in the region to create effective treatments for treating of hepatocellular carcinoma.

North America dominates the market due to the presence of key manufacturers of the product and treatment processes.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Hepatocellular Carcinoma Drugs Market Share Analysis

The hepatocellular carcinoma drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hepatocellular carcinoma drugs market.

Key players operating in the hepatocellular carcinoma drugs market include:

• Exelixis, Inc (U.S.)
• Merck & Co., Inc.(U.S.)
• AstraZeneca (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Lilly (U.S.)
• SillaJen, Inc (South Korea)
• Bayer AG (Germany)
• Janssen Global Services, LLC(미국)
• 파이저 주식회사(미국)
• 셀진 코퍼레이션(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 길리드 사이언스 주식회사(미국)
• GSK plc (영국)
• 다케다제약 주식회사(일본)
• 에자이 주식회사(일본)
• 암젠 주식회사(미국)
• 폴라리스 그룹(미국)
• 헤피온제약(미국)
• PROVECTUS BIOPHARMACEUTICALS, INC(미국)

SKU-50378